Elite Pharmaceuticals Reports Fiscal 2026 Revenue Growth of 77%
Elite Pharmaceuticals reported consolidated revenues of $148.9 million, representing a 77% increase driven by key product launches. This significant operational improvement highlights the company's successful expansion in generic pharmaceuticals.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day